Deck
A 42-year-old Korean test-handler maker that loads, thermally conditions, and sorts packaged memory chips for shipment — with more than half of FY2025 revenue from a single Chinese customer in the CXMT and YMTC supply chain.
FY2025 printed the strongest reported earnings in five years and the worst operating cash flow.
- Net income $7.0M; operating cash flow −$3.6M; free cash flow −$15.2M. The year that lit up the income statement burned cash on receivables and inventory as the China shipment book closed late on 30/60/10 deposit terms.
- The five-year scorecard says it is structural, not seasonal. FY2021–FY2025 cumulative net income sums to near zero against cumulative free cash flow of −$33.2M; the gap was plugged with $32.0M of convertible bonds, rights offerings, and bank borrowings, with the credit line 99.2% drawn.
- Q2 FY2026 (~14 August) is the single observable that resolves it. A positive OCF print on ≥$12M quarterly revenue with no fresh equity filing would refute the structural read; another NI-positive, OCF-negative quarter would confirm the bear case at 1.0× book.
YILINING PRECISION supplied 56.5% of FY2025 revenue — and Mirae cut ATE pricing nearly in half to land the volume.
ATE volume jumped 4× to 90 handlers while per-unit segment revenue collapsed from $665K to $346K — the signature of a price-taker buying volume with a concession, not a moat-protected vendor. Both downstream chipmakers in the YILINING chain (CXMT, YMTC) sit on the US Entity List; a single Federal Register notice extending controls to back-end test would reverse revenue toward the FY2023 $17M trough.
$21M of fixed assets came off the balance sheet in FY2025 without a matching cash receipt or disclosed disposal.
- The PP&E roundtrip. FY2024 capex was $24.7M against $0.7M of depreciation — 36.6× depreciation. Fixed assets swelled from $11.4M to $32.5M, then dropped back to $11.7M in FY2025 while non-current assets grew only $2.3M. The footnote that would resolve sale-leaseback vs reclassification vs capitalized opex has not been published.
- Restatement already on the record. Board resolution 2025-02-05 approved a formal restatement of FY2023 consolidated financials, with multiple (정정) amendments to single-customer supply contracts that followed.
- Thin oversight. Five-person board, one outside director at 74% attendance after the second resigned in August 2025, no audit committee, statutory auditor at a small Korean firm. The controlling chain (Nextern Roll Korea → Studio Santa Claus → ROA & Co) booked combined $16.3M in net losses last year.
+167% in twelve months, +94% over the past 30 days — RSI 78 and 30-day vol 120% put the rally at the edge of its useful range.
A fresh golden cross printed 2025-11-10 after a two-year death-cross window, and the November–December $9.7M and $6.9M supply contracts re-rated the stock back above the 200-day. The 5-for-1 forward split scheduled for 2026-07-27 is the optics moment the bear case watches for a follow-on capital action — the pattern that surrounded the 16:1 reverse split twelve months earlier.
Watchlist — the order book is real and book value is a floor, but cash conversion, forensics, and a parabolic tape make 1.0× P/B the wrong entry today.
- For. $35–41M of single-supply contracts disclosed since November 2025 already equal a full year of FY2025 revenue, and Q1 FY2026 printed $13.7M at a 23.6% operating margin against a 97.5%-utilized plant.
- For. The Korean non-US, non-Chinese supplier window is structurally favored — Cohu and Advantest US subsidiaries are blocked by BIS, Chinese domestic peer Changchuan is still qualifying, and trade press named Mirae among three Korean suppliers for post-IPO CXMT capex.
- Against. FY2025 $7.0M of net income did not produce cash, and the loss-making controlling chain above Mirae injected $4.5M downstream in January 2026 — bridge funding for a working-capital problem, not a vote of confidence.
- Against. Bear's blended floor of 0.4× book and 8× normalized through-cycle EBITDA both converge near $7.92 per share — a −57% gap from spot if Q2 OCF prints negative or any BIS notice extends to back-end test.
Watchlist to re-rate: Q2 FY2026 OCF in the mid-August DART filing; YILINING share and any new-counterparty name in 단일판매공급계약 disclosures; any capital-action filing within ±90 days of the 27-Jul forward split; BIS Federal Register language on back-end test handlers.